Drug Profile
AG 636
Alternative Names: AG-636Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Second-line therapy or greater) in USA (PO)
- 06 Apr 2021 Servier acquires oncology portfolio from Agios Pharmaceuticals
- 21 Dec 2020 Servier enters into purchase agreement to aquire oncology portfolio from Agios Pharmaceuticals